Anterogen.Co.,Ltd.

KOSDAQ:A065660 Stock Report

Market Cap: ₩152.3b

Anterogen.Co.Ltd Valuation

Is A065660 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A065660 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A065660's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A065660's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A065660?

Key metric: As A065660 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A065660. This is calculated by dividing A065660's market cap by their current revenue.
What is A065660's PS Ratio?
PS Ratio21.9x
Sales₩6.95b
Market Cap₩152.30b

Price to Sales Ratio vs Peers

How does A065660's PS Ratio compare to its peers?

The above table shows the PS ratio for A065660 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average28x
A011000 GeneOne Life Science
4.2xn/a₩159.3b
A182400 NKMAX
16.5xn/a₩172.7b
A293780 AptaBio Therapeutics
57xn/a₩165.6b
A083790 CG Invites
34.4xn/a₩191.9b
A065660 Anterogen.Co.Ltd
21.9xn/a₩152.3b

Price-To-Sales vs Peers: A065660 is good value based on its Price-To-Sales Ratio (21.9x) compared to the peer average (28x).

Price to Sales Ratio vs Industry

How does A065660's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 CompaniesPrice / SalesEstimated GrowthMarket Cap
A006280 GC Biopharma
1.2x9.1%US$1.31b
A096530 Seegene
2.7x15.7%US$748.81m
A086900 Medy-Tox
3.5x14.2%US$576.76m
A005250 Green Cross Holdings
0.3xn/aUS$528.08m
A065660 21.9xIndustry Avg. 10.5xNo. of Companies26PS01632486480+
26 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A065660 is expensive based on its Price-To-Sales Ratio (21.9x) compared to the KR Biotechs industry average (10.7x).

Price to Sales Ratio vs Fair Ratio

What is A065660's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A065660 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio21.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A065660's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 12:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anterogen.Co.,Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
JooYong KimKiwoom Securities Co., Ltd.